Biofarm (FRA:H3D) Cyclically Adjusted PS Ratio: (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H3D Biofarm SA FRA:H3D
70 GF Score
Price €0.24
GF Value €0.15
! 5 Warning Signs
View Full Analysis

What is Biofarm Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biofarm  (FRA:H3D) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Biofarm Cyclically Adjusted PS Ratio Related Terms


Biofarm Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Biofarm's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofarm Cyclically Adjusted PS Ratio Chart

Biofarm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.41 2.32 2.85 2.82 2.97

Biofarm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.59 3.00 3.00 2.97 4.31

FRA:H3D vs ZTS, UTHR, VTRS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofarm Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofarm's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biofarm's Cyclically Adjusted PS Ratio falls into.


FRA:H3D
70GF Score
Biofarm SA FRA:H3D
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofarm Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Biofarm's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Biofarm's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.018/330.2130*330.2130
=0.018

Current CPI (Mar. 2026) = 330.2130.

Biofarm Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.007 241.018 0.010
201609 0.007 241.428 0.010
201612 0.009 241.432 0.012
201703 0.007 243.801 0.009
201706 0.009 244.955 0.012
201709 0.008 246.819 0.011
201712 0.009 246.524 0.012
201803 0.008 249.554 0.011
201806 0.008 251.989 0.010
201809 0.009 252.439 0.012
201812 0.010 251.233 0.013
201903 0.009 254.202 0.012
201906 0.009 256.143 0.012
201909 0.008 256.759 0.010
201912 0.012 256.974 0.015
202003 0.012 258.115 0.015
202006 0.008 257.797 0.010
202009 0.010 260.280 0.013
202012 0.012 260.474 0.015
202103 0.012 264.877 0.015
202106 0.011 271.696 0.013
202109 0.012 274.310 0.014
202112 0.012 278.802 0.014
202203 0.015 287.504 0.017
202206 0.012 296.311 0.013
202209 0.014 296.808 0.016
202212 0.013 296.797 0.014
202303 0.018 301.836 0.020
202306 0.013 305.109 0.014
202309 0.013 307.789 0.014
202312 0.010 306.746 0.011
202403 0.014 312.332 0.015
202406 0.013 314.175 0.014
202409 0.017 315.301 0.018
202412 0.011 315.605 0.012
202503 0.018 319.799 0.019
202506 0.013 322.561 0.013
202509 0.019 324.800 0.019
202512 0.011 324.054 0.011
202603 0.018 330.213 0.018

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Biofarm (FRA:H3D) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of €0.24 is trading 56.7% above its estimated GF Value™ of €0.15.

Key valuation signals for FRA:H3D:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.15 vs. price of €0.24 (56.7% above fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the FRA:H3D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biofarm Business Description

Other Exchanges BIO:Romania
Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
70GF Score

Get the complete analysis for FRA:H3D

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.15
GF Value